Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DALYA trial of daratumumab + bortezomib + dexamethasone for relapsed or refractory plasmablastic lymphoma
2024-511635-94-00Phase 2Authorised
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Jul 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab, bortezomib and dexamethasone in plasmablastic lymphoma (PBL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Overall response rate. Planned start Jul 2022; status: authorised.
02
Drugs
daratumumabbortezomibdexamethasone
03
Conditions
plasmablastic lymphoma (PBL)
Beyond the preview
Go deeper on 2024-511635-94-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511635-94-00.